Clinical trials in Malaga – page 49

1 052 clinical trials in Malaga, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Malaga at a glance

1 052

clinical trials

Research sites4

Quick filters

1 052 trials in Malaga

Open in trial search

Prostate cancer

Not recruiting

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:Amgen Inc.

Contact Research Centre

Colorectal cancer metastatic

Not recruiting

A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Registered drugNo placebo

A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Registered drugNo placebo

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:BioNTech SE

Contact Research Centre

Ovarian cancer

Not recruiting

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

Registered drugNo placebo

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Tuvusertib
Sponsor:Merck Healthcare KGaA

Contact Research Centre

Obesity+1

Not recruiting

A study testing maridebart cafraglutide for weight loss in adults with overweight or obesity, with or without type 2 diabetes

Investigational

A study testing maridebart cafraglutide for weight loss in adults with overweight or obesity, with or without type 2 diabetes

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Not recruiting

Registered drugNo placebo

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:AstraZeneca AB

Contact Research Centre

Chronic obstructive pulmonary disease

Not recruiting

A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

Registered drug

A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Salbutamol
Sponsor:AstraZeneca AB

Contact Research Centre

Triple negative breast cancer

Not recruiting

A study testing zimberelimab, domvanalimab, and sacituzumab govitecan for patients with PD-L1 positive advanced triple-negative breast cancer

Registered drugNo placebo

A study testing zimberelimab, domvanalimab, and sacituzumab govitecan for patients with PD-L1 positive advanced triple-negative breast cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Domvanalimab
Sponsor:Medica Scientia Innovation Research S.L.

Contact Research Centre

Chronic obstructive pulmonary disease

Not recruiting

Study of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease Who Have Symptoms and a History of Flare-ups

Registered drug

Study of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease Who Have Symptoms and a History of Flare-ups

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Salbutamol Sulfate
Sponsor:AstraZeneca AB

Contact Research Centre

Factor VIII deficiency+1

Not recruiting

A study looking at the safety of switching from emicizumab to denecimig in adults and adolescents with haemophilia A with or without inhibitors

InvestigationalNo placebo

A study looking at the safety of switching from emicizumab to denecimig in adults and adolescents with haemophilia A with or without inhibitors

InvestigationalNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Novo Nordisk A/S

Contact Research Centre

Breast cancer+2

Not recruiting

A Study of Disitamab Vedotin for Adults with HER2 Expressing Advanced Breast Cancer

InvestigationalNo placebo

A Study of Disitamab Vedotin for Adults with HER2 Expressing Advanced Breast Cancer

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Disitamab Vedotin
Sponsor:Pfizer Inc.

Contact Research Centre

Chronic kidney disease

Not recruiting

A study to test how well empagliflozin works and how safe it is for children and teenagers with chronic kidney disease

Registered drug

A study to test how well empagliflozin works and how safe it is for children and teenagers with chronic kidney disease

Registered drug

Spain

Participants:0–17 years
Substances:Empagliflozin
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Malaga

What the registry says about research in the country

01 Autoimmune Conditions

Research focusing on innovative treatments for cutaneous lupus erythematosus and myasthenia gravis, evaluating new therapeutic approaches to improve patient outcomes.

Lupus skin manifestations
Neuromuscular disorders
Chronic urticaria management

Studies aim to assess novel therapies' effectiveness in reducing disease activity and improving daily living activities.

02 Infectious Diseases

Innovative vaccine development studies targeting COVID-19, cytomegalovirus, and respiratory syncytial virus, focusing on prevention and immune response.

Viral infections
Vaccine combinations
Pediatric prevention

Research emphasizes safety and immunogenicity in various population groups.

03 Oncology

Advanced studies in bladder cancer, colorectal cancer, and gastric cancer, evaluating targeted therapies and combination treatments.

Non-muscle invasive treatments
Metastatic disease management
Immunotherapy approaches

Trials focus on improving survival rates and treatment responses in various cancer types.

04 Respiratory Medicine

Research examining new treatments for chronic rhinosinusitis and COPD, with emphasis on symptom management and exacerbation prevention.

Airway inflammation
Pulmonary function
Quality of life measures

Studies evaluate novel therapeutic approaches for chronic respiratory conditions.

Back to Spain All countries